Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

Dose selection in seamless phase II/III clinical trials based on efficacy and toxicity

Tools
- Tools
+ Tools

Kimani, Peter Kung'u (2009) Dose selection in seamless phase II/III clinical trials based on efficacy and toxicity. PhD thesis, University of Warwick.

[img] PDF
WRAP_THESIS_Kimani_2009.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Download (855Kb)
Official URL: http://webcat.warwick.ac.uk/record=b2317838~S15

Abstract

Seamless phase II/III clinical trials are attractive in development of new drugs because they accelerate the drug development process. Seamless phase II/III trials are carried out in two stages. After stage 1 (phase II stage), an interim analysis is performed and a decision is made on whether to proceed to stage 2 (phase III stage). If the decision is to continue with further testing, some dose selection procedure is used to determine the set of doses to be tested in stage 2. Methodology exists for the analysis of such trials that allows complete flexibility of the choice of doses that continue to the second stage. There is very little work, however, on optimizing the selection of the doses. This is a challenging problem as it requires incorporation of the dose-response relationship, of the observed safety profile and of the planned analysis method. In this thesis we propose a dose-selection procedure for binary outcomes in adaptive seamless phase II/III clinical trials that incorporates the dose response relationship, and explicitly incorporates both efficacy and toxicity. The choice of the doses to continue to stage 2 is made by comparing the predictive power of the potential sets of doses which might continue to stage 2.

Item Type: Thesis or Dissertation (PhD)
Subjects: R Medicine > R Medicine (General)
Library of Congress Subject Headings (LCSH): Clinical trials -- Statistical methods, Drugs -- Testing -- Statistical methods, Clinical trials -- Methodology, Toxicity testing
Date: August 2009
Institution: University of Warwick
Theses Department: Department of Statistics
Thesis Type: PhD
Publication Status: Unpublished
Supervisor(s)/Advisor: Hutton, Jane L. ; Stallard, Nigel
Format of File: pdf
Extent: 151 leaves ; ill., charts
Language: eng
URI: http://wrap.warwick.ac.uk/id/eprint/2765

Request changes to a record

Actions (login required)

View Item View Item

Document Downloads

More statistics for this item...
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us